Bicycle Therapeutics plc (BCYC) Misses Q1 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 4, 2023 7:00 AM EDT- Continued progress across pipeline, including encouraging BT8009 Phase I dose escalation results presented in Q123
- Entered into a strategic collaboration with Novartis and expanded separate collaboration with the Division of Radiopharmaceutical Chemistry, German Cancer Research Center to develop Bicycle® Radio-Conjugates
- Cash position of $293.8 million at March 31, 2023 excludes $50 million upfront payment from Novartis, and is expected to provide financial runway into 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and... More
